Dr George Follows (Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK) talks with Dr Andrew Zelenetz (Memorial Sloan Kettering Cancer Centre, New York, USA) at the BSH 2016 conference in Glasgow.

Dr Zelenetz was presenting in Glasgow with a late breaking poster detailing the outcomes of a trial to treat relapsed chronic lymphocytic leukaemia with a combination of idelalisib, bendamustine and rituximab

The results of the trial report overwhelming efficacy of the combination compared to placebo or bendamustine with rituximab.

Dr Follows and Dr Zelenetz discuss the impact of these results, considering risks such as infection, and the value of the combined IBR arm of the trial against BR alone, or the as-yet-unreported IR arm.

Study details can be found here.

This video is supported by an educational grant from Gilead.